332 related articles for article (PubMed ID: 11668523)
21. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population.
Pjanova D; Engele L; Randerson-Moor JA; Harland M; Bishop DT; Newton Bishop JA; Taylor C; Debniak T; Lubinski J; Kleina R; Heisele O
Melanoma Res; 2007 Jun; 17(3):185-91. PubMed ID: 17505264
[TBL] [Abstract][Full Text] [Related]
22. Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors.
Sotillo R; Dubus P; Martín J; de la Cueva E; Ortega S; Malumbres M; Barbacid M
EMBO J; 2001 Dec; 20(23):6637-47. PubMed ID: 11726500
[TBL] [Abstract][Full Text] [Related]
23. Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes.
Soufir N; Bressac-de Paillerets B; Desjardins L; Lévy C; Bombled J; Gorin I; Schlienger P; Stoppa-Lyonnet D
Br J Cancer; 2000 Feb; 82(4):818-22. PubMed ID: 10732752
[TBL] [Abstract][Full Text] [Related]
24. Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma.
Sonoda Y; Yoshimoto T; Sekiya T
Oncogene; 1995 Nov; 11(10):2145-9. PubMed ID: 7478535
[TBL] [Abstract][Full Text] [Related]
25. Structural and functional analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in neuroblastoma.
Iolascon A; Giordani L; Moretti A; Tonini GP; Lo Cunsolo C; Mastropietro S; Borriello A; Ragione FD
Pediatr Res; 1998 Jan; 43(1):139-44. PubMed ID: 9432125
[TBL] [Abstract][Full Text] [Related]
26. Lack of germ-line mutations of CDK4, p16(INK4A), and p15(INK4B) in families with glioma.
Gao L; Liu L; van Meyel D; Cairncross G; Forsyth P; Kimmel D; Jenkins RB; Lassam NJ; Hogg D
Clin Cancer Res; 1997 Jun; 3(6):977-81. PubMed ID: 9815774
[TBL] [Abstract][Full Text] [Related]
27. Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations.
Eskandarpour M; Hashemi J; Kanter L; Ringborg U; Platz A; Hansson J
J Natl Cancer Inst; 2003 Jun; 95(11):790-8. PubMed ID: 12783933
[TBL] [Abstract][Full Text] [Related]
28. Mutations in the CDKN2A (p16INK4a) gene in microdissected sporadic primary melanomas.
Kumar R; Lundh Rozell B; Louhelainen J; Hemminki K
Int J Cancer; 1998 Jan; 75(2):193-8. PubMed ID: 9462707
[TBL] [Abstract][Full Text] [Related]
29. Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers.
Suzuki H; Zhou X; Yin J; Lei J; Jiang HY; Suzuki Y; Chan T; Hannon GJ; Mergner WJ; Abraham JM
Hum Mol Genet; 1995 Oct; 4(10):1883-7. PubMed ID: 8595411
[TBL] [Abstract][Full Text] [Related]
30. Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi.
Papp T; Pemsel H; Zimmermann R; Bastrop R; Weiss DG; Schiffmann D
J Med Genet; 1999 Aug; 36(8):610-4. PubMed ID: 10465111
[TBL] [Abstract][Full Text] [Related]
31. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
[TBL] [Abstract][Full Text] [Related]
32. Investigation of germline PTEN, p53, p16(INK4A)/p14(ARF), and CDK4 alterations in familial glioma.
Tachibana I; Smith JS; Sato K; Hosek SM; Kimmel DW; Jenkins RB
Am J Med Genet; 2000 May; 92(2):136-41. PubMed ID: 10797439
[TBL] [Abstract][Full Text] [Related]
33. Mutations of p16 and p15 tumor suppressor genes and replication errors contribute independently to the pathogenesis of sporadic malignant melanoma.
Matsumura Y; Nishigori C; Yagi T; Imamura S; Takebe H
Arch Dermatol Res; 1998 Apr; 290(4):175-80. PubMed ID: 9617435
[TBL] [Abstract][Full Text] [Related]
34. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas.
Helsing P; Nymoen DA; Ariansen S; Steine SJ; Maehle L; Aamdal S; Langmark F; Loeb M; Akslen LA; Molven A; Andresen PA
Genes Chromosomes Cancer; 2008 Feb; 47(2):175-84. PubMed ID: 18023021
[TBL] [Abstract][Full Text] [Related]
35. BRAF alterations are associated with complex mutational profiles in malignant melanoma.
Daniotti M; Oggionni M; Ranzani T; Vallacchi V; Campi V; Di Stasi D; Torre GD; Perrone F; Luoni C; Suardi S; Frattini M; Pilotti S; Anichini A; Tragni G; Parmiani G; Pierotti MA; Rodolfo M
Oncogene; 2004 Aug; 23(35):5968-77. PubMed ID: 15195137
[TBL] [Abstract][Full Text] [Related]
36. Analysis of G(1)/S checkpoint regulators in metastatic melanoma.
Sauroja I; Smeds J; Vlaykova T; Kumar R; Talve L; Hahka-Kemppinen M; Punnonen K; Jansèn CT; Hemminki K; Pyrhönen S
Genes Chromosomes Cancer; 2000 Aug; 28(4):404-14. PubMed ID: 10862049
[TBL] [Abstract][Full Text] [Related]
37. Intragenic mutations of the p16(INK4), p15(INK4B) and p18 genes in primary non-small-cell lung cancers.
Rusin MR; Okamoto A; Chorazy M; Czyzewski K; Harasim J; Spillare EA; Hagiwara K; Hussain SP; Xiong Y; Demetrick DJ; Harris CC
Int J Cancer; 1996 Mar; 65(6):734-9. PubMed ID: 8631583
[TBL] [Abstract][Full Text] [Related]
38. Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A.
Fuxe J; Akusjärvi G; Goike HM; Roos G; Collins VP; Pettersson RF
Cell Growth Differ; 2000 Jul; 11(7):373-84. PubMed ID: 10939591
[TBL] [Abstract][Full Text] [Related]
39. Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas.
Maelandsmo GM; Flørenes VA; Hovig E; Oyjord T; Engebraaten O; Holm R; Børresen AL; Fodstad O
Br J Cancer; 1996 Apr; 73(8):909-16. PubMed ID: 8611425
[TBL] [Abstract][Full Text] [Related]
40. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.
Borg A; Sandberg T; Nilsson K; Johannsson O; Klinker M; Måsbäck A; Westerdahl J; Olsson H; Ingvar C
J Natl Cancer Inst; 2000 Aug; 92(15):1260-6. PubMed ID: 10922411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
